This page is a secondary offer and is not affiliated with Myopharm

Corporate logo

Trading

Myopharm

Bringing the next diabetes block buster to market

Trade Now
research

INDUSTRY

Biotech & Life Sciences

STATUS

Trading

OPEN TO

Public

Investment Highlights

Company Overview

Products & Services

Additional Information

News

Trade Now
Ask Us a Question Or Express Interest

Investment Highlights

Developing TriGlytza™ – a novel first-in-class anti-inflammatory beta-cell centric oral combination formulation to be used as either a standalone or adjunct therapy to improve efficacy and optimise Additional Antidiabetic Diabetes Drugs (ADDs). 

Large unmet market 526 million Type 2 diabetics globally. 

Cash flow positive revenues from food for special medical purpose business.

Heading to the clinic for a Phase I trial.

Company Overview

Myopharm owns uniquely positioned TriGlytzaTM a proprietary technology that is US FDA approved with an IND which includes 68 metabolic diseases, indicated for Type 2 diabetics and treatment naïve patients as a standalone or adjunct therapy.

In addition, Myopharm holds a global portfolio of Food for Special Medical Purpose (FSMP) products for Type 2 Diabetes and weight loss products (35 unencumbered global patents). These products have 10 years of R&D backing from Adelaide University and the Baker IDI Institute. These solutions satisfy unmet medical market needs addressing approximately 800 million people worldwide. $8.1M spent on clinical research to date. Multiple out-licensing agreements executed in 2023. Omni-D is generating rapidly growing royalties and revenues, which help cover operating costs and support R&D activities.

sample

Products

OMNI-D

  • Controls dangerous glucose spikes
  • Smooths out glucose peaks and excursions which are key for preventing dementia, cognitive decline and organ damage
    • Backed with over $8.1M of clinical research
    • Clinical trials conducted at Baker IDI Heart and Diabetes Institute and Adelaide University – Clifton et al.
    • Omni-D

    Previous Funding


    May 2024

    $0.165 per share


    Raised $175,000

    Additional Information

    PrimaryMarkets Fees & Charges


    News

    March 2024

    The American Diabetes Association® (ADA) invites Myopharm to profile pioneering work on TriGlytzaTM

    July 2023

    MyopharmTM signs non-binding term sheet to acquire 100% of TriGlytzaTM rights.           

    March 2024

    Myopharm® Newsletter                                                                                                                                        

    June 2023

    Myopharm® strengthens licensing pipeline with BIO-E Australia by licensing WHOLESLIM product®                          

    December 2023

    Myopharm® completes purchase of TriGlytza Update                                                                                                                     

    May 2023

    Myopharm® strengthens board capabilities                                                                                                      

    Ask us a Question

    Send us a message and we'll connect soon

    Ask Us a Question

    Become a member

    Become a member and elevate your experience with us!

    Register now

    Already have an account? Login